Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.

Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, Kim C, Santic R, Schneeberger A, Mattner F, Schmidhuber S, Galabova G, Spencer B, Masliah E, Rissman RA.

Alzheimers Dement. 2019 Aug 1. pii: S1552-5260(19)30071-8. doi: 10.1016/j.jalz.2019.02.002. [Epub ahead of print]

PMID:
31378574
2.

Integrating Gene and Protein Expression Reveals Perturbed Functional Networks in Alzheimer's Disease.

Canchi S, Raao B, Masliah D, Rosenthal SB, Sasik R, Fisch KM, De Jager PL, Bennett DA, Rissman RA.

Cell Rep. 2019 Jul 23;28(4):1103-1116.e4. doi: 10.1016/j.celrep.2019.06.073.

3.

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2050. [Epub ahead of print]

4.

Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial.

Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer’s Disease Cooperative Study TCAD Study Group.

JAMA Neurol. 2019 Jul 8. doi: 10.1001/jamaneurol.2019.1868. [Epub ahead of print]

5.

Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).

Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA.

J Alzheimers Dis. 2019;70(1):131-138. doi: 10.3233/JAD-190322.

PMID:
31156181
6.

Early neuronal accumulation of DNA double strand breaks in Alzheimer's disease.

Shanbhag NM, Evans MD, Mao W, Nana AL, Seeley WW, Adame A, Rissman RA, Masliah E, Mucke L.

Acta Neuropathol Commun. 2019 May 17;7(1):77. doi: 10.1186/s40478-019-0723-5.

7.

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.

Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White Iii CL, Yu L, Schneider JA.

Brain. 2019 Jun 1;142(6):1503-1527. doi: 10.1093/brain/awz099. Erratum in: Brain. 2019 May 31;:.

8.

Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer's disease dementia.

Winston CN, Goetzl EJ, Schwartz JB, Elahi FM, Rissman RA.

Alzheimers Dement (Amst). 2019 Jan 9;11:61-66. doi: 10.1016/j.dadm.2018.11.002. eCollection 2019 Dec.

9.

Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Spencer B, Trinh I, Rockenstein E, Mante M, Florio J, Adame A, El-Agnaf OMA, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.

PMID:
30849508
10.

Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD.

Pottier C, Ren Y, Perkerson RB 3rd, Baker M, Jenkins GD, van Blitterswijk M, DeJesus-Hernandez M, van Rooij JGJ, Murray ME, Christopher E, McDonnell SK, Fogarty Z, Batzler A, Tian S, Vicente CT, Matchett B, Karydas AM, Hsiung GR, Seelaar H, Mol MO, Finger EC, Graff C, Öijerstedt L, Neumann M, Heutink P, Synofzik M, Wilke C, Prudlo J, Rizzu P, Simon-Sanchez J, Edbauer D, Roeber S, Diehl-Schmid J, Evers BM, King A, Mesulam MM, Weintraub S, Geula C, Bieniek KF, Petrucelli L, Ahern GL, Reiman EM, Woodruff BK, Caselli RJ, Huey ED, Farlow MR, Grafman J, Mead S, Grinberg LT, Spina S, Grossman M, Irwin DJ, Lee EB, Suh E, Snowden J, Mann D, Ertekin-Taner N, Uitti RJ, Wszolek ZK, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Hodges JR, Piguet O, Geier EG, Yokoyama JS, Rissman RA, Rogaeva E, Keith J, Zinman L, Tartaglia MC, Cairns NJ, Cruchaga C, Ghetti B, Kofler J, Lopez OL, Beach TG, Arzberger T, Herms J, Honig LS, Vonsattel JP, Halliday GM, Kwok JB, White CL 3rd, Gearing M, Glass J, Rollinson S, Pickering-Brown S, Rohrer JD, Trojanowski JQ, Van Deerlin V, Bigio EH, Troakes C, Al-Sarraj S, Asmann Y, Miller BL, Graff-Radford NR, Boeve BF, Seeley WW, Mackenzie IRA, van Swieten JC, Dickson DW, Biernacka JM, Rademakers R.

Acta Neuropathol. 2019 Jun;137(6):879-899. doi: 10.1007/s00401-019-01962-9. Epub 2019 Feb 9.

PMID:
30739198
11.

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies.

Hassen GW, Kesner L, Stracher A, Shulman A, Rockenstein E, Mante M, Adame A, Overk C, Rissman RA, Masliah E.

Sci Rep. 2018 Dec 27;8(1):18083. doi: 10.1038/s41598-018-35729-1.

12.

Neuronal Exosome-Derived Human Tau is Toxic to Recipient Mouse Neurons in vivo.

Winston CN, Aulston B, Rockenstein EM, Adame A, Prikhodko O, Dave KN, Mishra P, Rissman RA, Yuan SH.

J Alzheimers Dis. 2019;67(2):541-553. doi: 10.3233/JAD-180776.

PMID:
30584143
13.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O'Bryant SE; International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association.

Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13.

14.

Targeted Mutation (R100W) of the Gene Encoding NGF Leads to Deficits in the Peripheral Sensory Nervous System.

Yang W, Sung K, Zhou F, Xu W, Rissman RA, Ding J, Wu C.

Front Aging Neurosci. 2018 Nov 13;10:373. doi: 10.3389/fnagi.2018.00373. eCollection 2018.

15.

Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease.

Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, Percival-Alwyn J, Schultz A, Properzi M, Johnson K, Selkoe DJ, Sperling RA, Patel P, Zetterberg H, Galasko D, Schott JM, Walsh DM.

Alzheimers Dement. 2019 Mar;15(3):487-496. doi: 10.1016/j.jalz.2018.09.010. Epub 2018 Nov 9.

16.

Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.

Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA.

J Alzheimers Dis. 2018;66(4):1539-1548. doi: 10.3233/JAD-180789.

PMID:
30412501
17.

Growth Hormone-Releasing Hormone Modulation of Neuronal Exosome Biomarkers in Mild Cognitive Impairment.

Winston CN, Goetzl EJ, Baker LD, Vitiello MV, Rissman RA.

J Alzheimers Dis. 2018;66(3):971-981. doi: 10.3233/JAD-180302.

18.

A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease.

O'Bryant SE, Zhang F, Johnson LA, Hall J, Edwards M, Grammas P, Oh E, Lyketsos CG, Rissman RA.

J Alzheimers Dis. 2018;66(1):97-104. doi: 10.3233/JAD-180619.

19.

T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation.

Chen XQ, Fang F, Florio JB, Rockenstein E, Masliah E, Mobley WC, Rissman RA, Wu C.

Traffic. 2018 Nov;19(11):840-853. doi: 10.1111/tra.12610. Epub 2018 Sep 12.

20.

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.

Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E.

Mol Neurodegener. 2018 Aug 9;13(1):43. doi: 10.1186/s13024-018-0276-2.

21.

Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Spencer B, Brüschweiler S, Sealey-Cardona M, Rockenstein E, Adame A, Florio J, Mante M, Trinh I, Rissman RA, Konrat R, Masliah E.

Acta Neuropathol. 2018 Jul;136(1):69-87. doi: 10.1007/s00401-018-1869-0. Epub 2018 Jun 14.

22.

Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study.

Pottier C, Zhou X, Perkerson RB 3rd, Baker M, Jenkins GD, Serie DJ, Ghidoni R, Benussi L, Binetti G, López de Munain A, Zulaica M, Moreno F, Le Ber I, Pasquier F, Hannequin D, Sánchez-Valle R, Antonell A, Lladó A, Parsons TM, Finch NA, Finger EC, Lippa CF, Huey ED, Neumann M, Heutink P, Synofzik M, Wilke C, Rissman RA, Slawek J, Sitek E, Johannsen P, Nielsen JE, Ren Y, van Blitterswijk M, DeJesus-Hernandez M, Christopher E, Murray ME, Bieniek KF, Evers BM, Ferrari C, Rollinson S, Richardson A, Scarpini E, Fumagalli GG, Padovani A, Hardy J, Momeni P, Ferrari R, Frangipane F, Maletta R, Anfossi M, Gallo M, Petrucelli L, Suh E, Lopez OL, Wong TH, van Rooij JGJ, Seelaar H, Mead S, Caselli RJ, Reiman EM, Noel Sabbagh M, Kjolby M, Nykjaer A, Karydas AM, Boxer AL, Grinberg LT, Grafman J, Spina S, Oblak A, Mesulam MM, Weintraub S, Geula C, Hodges JR, Piguet O, Brooks WS, Irwin DJ, Trojanowski JQ, Lee EB, Josephs KA, Parisi JE, Ertekin-Taner N, Knopman DS, Nacmias B, Piaceri I, Bagnoli S, Sorbi S, Gearing M, Glass J, Beach TG, Black SE, Masellis M, Rogaeva E, Vonsattel JP, Honig LS, Kofler J, Bruni AC, Snowden J, Mann D, Pickering-Brown S, Diehl-Schmid J, Winkelmann J, Galimberti D, Graff C, Öijerstedt L, Troakes C, Al-Sarraj S, Cruchaga C, Cairns NJ, Rohrer JD, Halliday GM, Kwok JB, van Swieten JC, White CL 3rd, Ghetti B, Murell JR, Mackenzie IRA, Hsiung GR, Borroni B, Rossi G, Tagliavini F, Wszolek ZK, Petersen RC, Bigio EH, Grossman M, Van Deerlin VM, Seeley WW, Miller BL, Graff-Radford NR, Boeve BF, Dickson DW, Biernacka JM, Rademakers R.

Lancet Neurol. 2018 Jun;17(6):548-558. doi: 10.1016/S1474-4422(18)30126-1. Epub 2018 Apr 30.

23.

Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS; AAV2-NGF Study Team.

JAMA Neurol. 2018 Jul 1;75(7):834-841. doi: 10.1001/jamaneurol.2018.0233.

24.

Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.

Arner A, Rockenstein E, Mante M, Florio J, Masliah D, Salehi B, Adame A, Overk C, Masliah E, Rissman RA.

J Alzheimers Dis. 2018;61(3):1201-1219. doi: 10.3233/JAD-170388.

25.

Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.

Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, Adame A, Trinh I, Kim C, Overk C, Masliah E, Rissman RA.

J Neurosci. 2018 Jan 24;38(4):1000-1014. doi: 10.1523/JNEUROSCI.1170-17.2017. Epub 2017 Dec 15.

26.

NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism.

Tu S, Akhtar MW, Escorihuela RM, Amador-Arjona A, Swarup V, Parker J, Zaremba JD, Holland T, Bansal N, Holohan DR, Lopez K, Ryan SD, Chan SF, Yan L, Zhang X, Huang X, Sultan A, McKercher SR, Ambasudhan R, Xu H, Wang Y, Geschwind DH, Roberts AJ, Terskikh AV, Rissman RA, Masliah E, Lipton SA, Nakanishi N.

Nat Commun. 2017 Nov 14;8(1):1488. doi: 10.1038/s41467-017-01563-8.

27.

Epigenetic suppression of hippocampal calbindin-D28k by ΔFosB drives seizure-related cognitive deficits.

You JC, Muralidharan K, Park JW, Petrof I, Pyfer MS, Corbett BF, LaFrancois JJ, Zheng Y, Zhang X, Mohila CA, Yoshor D, Rissman RA, Nestler EJ, Scharfman HE, Chin J.

Nat Med. 2017 Nov;23(11):1377-1383. doi: 10.1038/nm.4413. Epub 2017 Oct 16.

28.

PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).

Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC; Down Syndrome Biomarker Initiative and the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;60(2):439-450. doi: 10.3233/JAD-170390.

PMID:
28946567
29.

Corticotropin-releasing factor receptor-1 modulates biomarkers of DNA oxidation in Alzheimer's disease mice.

Zhang C, Rissman RA.

PLoS One. 2017 Jul 27;12(7):e0181367. doi: 10.1371/journal.pone.0181367. eCollection 2017.

30.

Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS.

Alzheimers Dement (N Y). 2016 Jun;2(2):69-81. doi: 10.1016/j.trci.2016.02.004.

31.

Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease.

Fang F, Yang W, Florio JB, Rockenstein E, Spencer B, Orain XM, Dong SX, Li H, Chen X, Sung K, Rissman RA, Masliah E, Ding J, Wu C.

Sci Rep. 2017 Jun 20;7(1):3868. doi: 10.1038/s41598-017-04232-4.

32.

Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Reilly P, Winston CN, Baron KR, Trejo M, Rockenstein EM, Akers JC, Kfoury N, Diamond M, Masliah E, Rissman RA, Yuan SH.

Neurobiol Dis. 2017 Oct;106:222-234. doi: 10.1016/j.nbd.2017.06.005. Epub 2017 Jun 10.

33.

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology.

Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, Rissman RA.

Acta Neuropathol Commun. 2017 Jun 9;5(1):46. doi: 10.1186/s40478-017-0445-5.

34.

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

El-Agnaf O, Overk C, Rockenstein E, Mante M, Florio J, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2017 Aug;104:85-96. doi: 10.1016/j.nbd.2017.05.002. Epub 2017 May 2.

35.

Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.

Wagner SL, Rynearson KD, Duddy SK, Zhang C, Nguyen PD, Becker A, Vo U, Masliah D, Monte L, Klee JB, Echmalian CM, Xia W, Quinti L, Johnson G, Lin JH, Kim DY, Mobley WC, Rissman RA, Tanzi RE.

J Pharmacol Exp Ther. 2017 Jul;362(1):31-44. doi: 10.1124/jpet.117.240861. Epub 2017 Apr 17.

36.

A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

37.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

38.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS.

J Neuroinflammation. 2017 Jan 3;14(1):1. doi: 10.1186/s12974-016-0779-0.

39.

Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.

Sokolow S, Li X, Chen L, Taylor KD, Rotter JI, Rissman RA, Aisen PS, Apostolova LG.

J Alzheimers Dis. 2017;56(1):229-237. doi: 10.3233/JAD-160562.

40.

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H; Biofluid Based Biomarker Professional Interest Area.

Alzheimers Dement. 2017 Jan;13(1):45-58. doi: 10.1016/j.jalz.2016.09.014. Epub 2016 Nov 18.

41.

Meditation and vacation effects have an impact on disease-associated molecular phenotypes.

Epel ES, Puterman E, Lin J, Blackburn EH, Lum PY, Beckmann ND, Zhu J, Lee E, Gilbert A, Rissman RA, Tanzi RE, Schadt EE.

Transl Psychiatry. 2016 Aug 30;6(8):e880. doi: 10.1038/tp.2016.164.

42.

Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, Mante M, Adame A, Florio J, Rockenstein E, Masliah E.

J Neurosci. 2016 Jul 27;36(30):7971-84. doi: 10.1523/JNEUROSCI.0775-16.2016.

43.

Higher Brain Perfusion May Not Support Memory Functions in Cognitively Normal Carriers of the ApoE ε4 Allele Compared to Non-Carriers.

Zlatar ZZ, Bischoff-Grethe A, Hays CC, Liu TT, Meloy MJ, Rissman RA, Bondi MW, Wierenga CE.

Front Aging Neurosci. 2016 Jun 24;8:151. doi: 10.3389/fnagi.2016.00151. eCollection 2016.

44.

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.

Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA.

Alzheimers Dement (Amst). 2016 May 7;3:63-72. doi: 10.1016/j.dadm.2016.04.001. eCollection 2016.

45.

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.

Gelmont D, Thomas RG, Britt J, Dyck-Jones JA, Doralt J, Fritsch S, Brewer JB, Rissman RA, Aisen P.

Alzheimers Dement (N Y). 2016 Jun 21;2(2):131-139. doi: 10.1016/j.trci.2016.06.003. eCollection 2016 Jun.

46.

Lack of Influence of Apolipoprotein E Status on Cognition or Brain Structure in Professional Fighters.

Banks SJ, Miller JB, Rissman RA, Bernick CB.

J Neurotrauma. 2017 Jan 15;34(2):380-384. doi: 10.1089/neu.2016.4453. Epub 2016 Jun 27.

47.

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges.

O'Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J, Zetterberg H, Lovestone S, Gupta V, Graff-Radford N, Martins R, Jeromin A, Waring S, Oh E, Kling M, Baker LD, Hampel H.

Alzheimers Dement (Amst). 2015 Dec 29;3:27-34. doi: 10.1016/j.dadm.2015.12.003. eCollection 2016.

48.

Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport.

Le MH, Weissmiller AM, Monte L, Lin PH, Hexom TC, Natera O, Wu C, Rissman RA.

PLoS One. 2016 Jan 20;11(1):e0147250. doi: 10.1371/journal.pone.0147250. eCollection 2016.

49.

Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.

Zhang C, Kuo CC, Moghadam SH, Monte L, Campbell SN, Rice KC, Sawchenko PE, Masliah E, Rissman RA.

Alzheimers Dement. 2016 May;12(5):527-37. doi: 10.1016/j.jalz.2015.09.007. Epub 2015 Nov 7.

50.

Reproductive Stage and Modulation of Stress-Induced Tau Phosphorylation in Female Rats.

Steinmetz D, Ramos E, Campbell SN, Morales T, Rissman RA.

J Neuroendocrinol. 2015 Nov;27(11):827-34. doi: 10.1111/jne.12323.

Supplemental Content

Loading ...
Support Center